<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02963649</url>
  </required_header>
  <id_info>
    <org_study_id>APV-IN.PACT BTK OUS</org_study_id>
    <nct_id>NCT02963649</nct_id>
  </id_info>
  <brief_title>IN.PACT BTK Randomized Study to Assess Safety and Efficacy of IN.PACT 014 vs. PTA</brief_title>
  <official_title>Randomized Study of IN.PACT 014 Paclitaxel-Coated Percutaneous Transluminal Angioplasty Balloon Catheter vs. Standard Percutaneous Transluminal Angioplasty for the Treatment of Chronic Total Occlusions in the Infrapopliteal Arteries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Endovascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Endovascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the safety and efficacy of the paclitaxel drug-eluting balloon IN.PACT 014 versus&#xD;
      conventional percutaneous transluminal angioplasty (PTA) for the treatment of patients with&#xD;
      chronic total occlusions in the infrapopliteal arteries.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Actual">October 7, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Late lumen loss (LLL) at 9 months</measure>
    <time_frame>9 Months</time_frame>
    <description>Late lumen loss (LLL) at 9 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Safety Endpoint</measure>
    <time_frame>30 days and 9 Months</time_frame>
    <description>A composite of freedom from device- and procedure-related mortality within 30 days, freedom from major target limb amputation and freedom from clinically-driven target lesion revascularization (CD-TLR) within 9 months post-index procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Event (MAE) rate</measure>
    <time_frame>through 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>defined as a composite of all-cause mortality, target limb major amputation and clinically-driven target lesion revascularization (CD-TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Status of wound healing</measure>
    <time_frame>at 30 days, 3, 6, 9, 12, 24 and 36 months</time_frame>
    <description>completely healed - improvement - unchanged - worsened</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of thrombosis at the target lesion</measure>
    <time_frame>through 30 days, 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Rate of thrombosis at the target lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>at the time of procedure</time_frame>
    <description>is defined as successful drug delivery, balloon inflation, deflation and retrieval of the intact study device without burst below the rated burst pressure (RBP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical success</measure>
    <time_frame>up to discharge visit</time_frame>
    <description>is defined as residual stenosis of ≤ 30% without procedural complications (death, major target limb amputation, thrombosis of the target lesion, or target vessel revascularization (TVR))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional flow assessment</measure>
    <time_frame>at 3, 6, 9, 12, 24 and 36 months</time_frame>
    <description>is defined as absence of target lesion occlusion (no flow) assessed by duplex ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death of any cause and cardiovascular-related deaths</measure>
    <time_frame>through 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Death of any cause and cardiovascular-related deaths</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Target Limb Amputation rate</measure>
    <time_frame>through 30 days, 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Major Target Limb Amputation rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanically-driven Target Lesion Revascularization (TLR) rate</measure>
    <time_frame>through 37 days</time_frame>
    <description>Mechanically-driven Target Lesion Revascularization (TLR) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR) rate</measure>
    <time_frame>through 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Target Lesion Revascularization (TLR) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Lesion Revascularization (CD-TLR) rate</measure>
    <time_frame>through 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Clinically-driven Target Lesion Revascularization (CD-TLR) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR) rate</measure>
    <time_frame>through 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Target Vessel Revascularization (TVR) rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically-driven Target Vessel Revascularization (CD-TVR) rate</measure>
    <time_frame>through 3, 6, 9, 12, 24, 36, 48 and 60 months</time_frame>
    <description>Clinically-driven Target Vessel Revascularization (CD-TVR) rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Critical Limb Ischemia</condition>
  <condition>Peripheral Arterial Disease</condition>
  <arm_group>
    <arm_group_label>drug-eluting balloon IN.PACT 014</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>product is indicated for PTA in patients with obstructive disease of peripheral arteries with paclitaxel drug - elution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard angioplasty balloon</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard PTA balloon</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>DCB</intervention_name>
    <description>Drug Coated Balloon</description>
    <arm_group_label>drug-eluting balloon IN.PACT 014</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PTA</intervention_name>
    <description>Percutaneous Transluminal Angioplasty</description>
    <arm_group_label>Standard angioplasty balloon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. Subject has been informed of the nature of the study, agrees to participate and has&#xD;
             signed an EC approved consent form.&#xD;
&#xD;
          3. Female subjects of childbearing potential have a negative pregnancy test ≤7 days&#xD;
             before the procedure and are willing to use a reliable method of birth control for the&#xD;
             duration of study participation.&#xD;
&#xD;
          4. Subject has documented chronic Critical Limb Ischemia (CLI) in the target limb prior&#xD;
             to the study procedure with Rutherford Clinical Category 4 or 5.&#xD;
&#xD;
          5. Subjects with documented infection grade 0-2 and ischemia grade 2-3 according to WIfi&#xD;
             classification.&#xD;
&#xD;
          6. Life expectancy &gt;1 year in the Investigator's opinion.&#xD;
&#xD;
          7. Reference Vessel Diameter (RVD) 2 - 4 mm, and confirmed by DUS assessment.&#xD;
&#xD;
          8. Total occlusions with total lesion length ≥ 40 mm.&#xD;
&#xD;
          9. Lesion must be located in the infrapopliteal arteries and above the ankle joint.&#xD;
&#xD;
         10. Multiple lesions can be treated if located in separate vessels.&#xD;
&#xD;
         11. Presence of documented run-off to the foot.&#xD;
&#xD;
         12. Inflow free from flow-limiting lesion confirmed by angiography.&#xD;
&#xD;
         13. Successful pre-dilatation of the (entire) target lesion.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject unwilling or unlikely to comply to the appropriate follow-up times for the&#xD;
             duration of the study.&#xD;
&#xD;
          2. Planned index limb amputation above the metatarsal level, or any other planned major&#xD;
             surgery within 30 days pre or post-procedure.&#xD;
&#xD;
          3. Lesion and/or occlusions located or extending in the popliteal artery or below the&#xD;
             ankle joint space.&#xD;
&#xD;
          4. Significant inflow lesion or occlusion in the ipsilateral iliac, SFA and popliteal&#xD;
             arteries left untreated.&#xD;
&#xD;
          5. Failure to obtain ≤ 30% residual stenosis in pre-existing, hemodynamically significant&#xD;
             inflow lesions in the ipsilateral iliac, SFA and popliteal artery.&#xD;
&#xD;
          6. Prior stent(s) or bypass surgery within the target vessel(s) (including stents placed&#xD;
             within target vessels during the index procedure prior to randomization.&#xD;
&#xD;
          7. Previous DCB procedure in the target vessel within 6 months prior to index procedure.&#xD;
&#xD;
          8. Aneurysm in the target vessel.&#xD;
&#xD;
          9. Angiographic evidence of thrombus within target limb.&#xD;
&#xD;
         10. Pre-dilatation resulted in major (≥ Grade D) flow-limiting dissection or residual&#xD;
             stenosis &gt; 30%.&#xD;
&#xD;
         11. Use of alternative therapy e.g. atherectomy, cutting balloon, laser, radiation&#xD;
             therapy, stents as part of target vessel treatment.&#xD;
&#xD;
         12. Recent MI or stroke &lt; 30 days prior to the index procedure.&#xD;
&#xD;
         13. Heart failure with Ejection Fraction &lt; 30%.&#xD;
&#xD;
         14. Known or suspected active infection at the time of the index procedure, excluding an&#xD;
             infection of a lower extremity wound on the target limb.&#xD;
&#xD;
         15. Subjects with infection grade 3 and ischemia grade 0 and 1 according to the Wifi&#xD;
             classification.&#xD;
&#xD;
         16. Subjects with neutrotrophic ulcers, heel pressure ulcers or calcaneal ulcers with a&#xD;
             risk of major amputation.&#xD;
&#xD;
         17. Subjects with documented active osteomyelitis, excluding the phalanges, that is beyond&#xD;
             cortical involvement of the bone per clinical judgement.&#xD;
&#xD;
         18. Impaired renal function (GFR &lt;20 mL/min) and patients on dialysis.&#xD;
&#xD;
         19. Subject with vasculitis, systemic Lupus Erythematosus or Polymyalgia Rheumatica on&#xD;
             active treatment.&#xD;
&#xD;
         20. Patient receiving systemic corticosteroid therapy.&#xD;
&#xD;
         21. Known allergies or sensitivities to heparin, aspirin (ASA), other&#xD;
             anticoagulant/anti-platelet therapies which could not be substituted, and/or&#xD;
             paclitaxel or an allergy to contrast media that cannot be adequately pre-treated prior&#xD;
             to the index procedure.&#xD;
&#xD;
         22. The patient is currently enrolled in another investigational device or drug trial that&#xD;
             is interfering with the endpoints of this study.&#xD;
&#xD;
         23. Female subjects who are breastfeeding at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AZ Sint Blasius</name>
      <address>
        <city>Dendermonde</city>
        <state>East-Flanders</state>
        <zip>9200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ZOL Genk</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionaal Ziekenhuis Heilig Hart</name>
      <address>
        <city>Tienen</city>
        <state>Vlaams Brabant</state>
        <zip>3300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Guillaume et Rene Laennec - Centre Hospitalier Universitaire</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Patras</name>
      <address>
        <city>Patras</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Multimedica</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>Lombardy</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Cecilia Hospital</name>
      <address>
        <city>Cotignola</city>
        <state>Ravenna</state>
        <zip>48033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Donato</name>
      <address>
        <city>Arezzo</city>
        <zip>50200</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <removed_countries>
    <country>Netherlands</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 9, 2016</study_first_submitted>
  <study_first_submitted_qc>November 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2016</study_first_posted>
  <last_update_submitted>January 20, 2021</last_update_submitted>
  <last_update_submitted_qc>January 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug-eluting angioplasty balloon, Drug coated angioplasty balloon, Experimental, percutaneous transluminal angioplasty (PTA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Arterial Disease</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

